- Home
- LPG vs ADPT Comparison
LPG vs ADPT Comparison
Compare LPG & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- ADPT
- Stock Information
- Founded
- LPG 2013
- ADPT 2009
- Country
- LPG United States
- ADPT United States
- Employees
- LPG N/A
- ADPT N/A
- Industry
- LPG Marine Transportation
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPG Consumer Discretionary
- ADPT Health Care
- Exchange
- LPG Nasdaq
- ADPT Nasdaq
- Market Cap
- LPG 913.3M
- ADPT 1.1B
- IPO Year
- LPG 2014
- ADPT 2019
- Fundamental
- Price
- LPG $22.00
- ADPT $9.03
- Analyst Decision
- LPG Strong Buy
- ADPT Buy
- Analyst Count
- LPG 1
- ADPT 6
- Target Price
- LPG $35.00
- ADPT $9.83
- AVG Volume (30 Days)
- LPG 689.5K
- ADPT 3.0M
- Earning Date
- LPG 05-21-2025
- ADPT 05-01-2025
- Dividend Yield
- LPG 14.53%
- ADPT N/A
- EPS Growth
- LPG N/A
- ADPT N/A
- EPS
- LPG 3.87
- ADPT N/A
- Revenue
- LPG $416,947,918.00
- ADPT $189,527,000.00
- Revenue This Year
- LPG N/A
- ADPT $21.20
- Revenue Next Year
- LPG $10.11
- ADPT $21.99
- P/E Ratio
- LPG $5.70
- ADPT N/A
- Revenue Growth
- LPG N/A
- ADPT 8.61
- 52 Week Low
- LPG $16.66
- ADPT $2.99
- 52 Week High
- LPG $51.66
- ADPT $10.28
- Technical
- Relative Strength Index (RSI)
- LPG 55.95
- ADPT 57.82
- Support Level
- LPG $21.05
- ADPT $8.38
- Resistance Level
- LPG $22.59
- ADPT $9.51
- Average True Range (ATR)
- LPG 0.65
- ADPT 0.66
- MACD
- LPG 0.13
- ADPT 0.16
- Stochastic Oscillator
- LPG 75.61
- ADPT 63.02
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).